Allergan plc, of Dublin, presented new data highlighting the in vitro activity of Avycaz (ceftazidime and avibactam) against several species of gram-negative pathogens, including certain strains of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and Pseudomonas aeruginosa.